Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

t an expanded cohort of patients at the maximum tolerated dose.  The company has cleared a safety review after dosing the 5 mg/kg cohort and has authorization to start enrolling patients at 10 mg/kg.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673.  In the first quarter of 2011, the company initiated a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors.  In July 2011, the company initiated a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  The primary objective of the studies is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.  

  • Preclinical Programs

  • BMN-111 for Achondroplasia: Regulatory interactions are underway, and BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth, for achondroplasia, the most common form of dwarfism.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and six months ended June 30, 2011 and June 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
    (Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
    (Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
    Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
    ...  Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... granted a positive opinion for conditional approval from ... Products for Human Use ("CHMP"). Based on the ... authorization for Pixuvri should be granted by the ...
    ...  A new look at the three most highly regarded ... of its kind to consider long-term cost and quality ... prostatectomy surgery and brachytherapy to be less expensive and ... the treatment of prostate cancer . ...
    Cached Medicine Technology:European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 2European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 3European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 4European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 5Prostate Cancer Treatment Options Go Head-to-Head 2Prostate Cancer Treatment Options Go Head-to-Head 3
    (Date:4/22/2014)... 22, 2014: The Association for Molecular Pathology (AMP) ... of Molecular Diagnostics on recommendations for a ... master,s levels of education. The report was prepared ... Force of the AMP Training and Education Committee. ... of educating future medical laboratory scientists appropriately in ...
    (Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
    (Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
    (Date:4/22/2014)... 10 Americans support mandated coverage of birth control medications, ... the University of Michigan Health System. , Women, blacks, ... at home, and adults with private or public insurance ... universal coverage of birth control medications, according to the ... American Medical Association ( JAMA ). , Individuals ...
    (Date:4/22/2014)... German . Scientists ... Vienna and the Medical University of Vienna, together with colleagues ... RNA, such as viral genetic information, is prevented from entering ... viral infection, the protein ADAR1 moves from the cell nucleus ... inhibit reproduction of the virus. But how is the human ...
    Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
    ... government, through the U.S. Agency for International Development (USAID), is ... Assistance Response Team (DART) to help combat the cholera outbreak ... than $4.6 million for emergency water, sanitation, and hygiene program ... , This new funding will provide additional ...
    ... 11 Mary Beth Bolton, MD, FACP, a Detroit internal ... by the Michigan State Medical Society (MSMS). , ... Chief Medical Officer with Health Alliance Plan (HAP) since 2000, ... career-long commitment to improving primary patient care through increasing access, ...
    ... to "Tell Their Stories" , , ... that healthcare reform will be a top priority in his ... serve as health and human services secretary, is the leader ... to help with reform efforts by sharing their healthcare experiences ...
    ... million people die every year from infectious diseases, ... The discovery of penicillin to treat bacterial ... previously incurable virus diseases such as polio and ... mid-20th century. , Recently, spectacular advances in medical ...
    ... company, announced today that beginning January 1, 2009, ... for incomplete spinal cord injury patients suffering from ... Medicare and Medicaid Services (CMS) establishes a new ... devices including the NESS L300™ Foot Drop System. ...
    ... GLENVIEW, IL, Dec. 11, 2008 Federal funding for pain research ... according to a new study published in The Journal of ... only 0.6 percent of all grants awarded by the National Institutes ... the U.S. , "This startling finding shows the government,s ...
    Cached Medicine News:Health News:USAID Provides Additional $6.2M for Zimbabwe Cholera Outbreak 2Health News:Mary Beth Bolton, MD, Named 'Woman Physician of the Year' by Michigan State Medical Society 2Health News:Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns 2Health News:Mathematical models of adaptive immunity 2Health News:Mathematical models of adaptive immunity 3Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Study shows major pain research funding decline at NIH 2
    MDI will work with your facility to determine the best interim lab to fit your needs and your site....
    ... large number of mobile, modular and transportable ... fleet. The labs are typically leased to ... The Cath Lab Leasing Company allows hospitals ... upgrading existing equipment, initiating a new service ...
    ... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
    ... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
    Medicine Products: